Table 2.
Previously Reported Cases of the Effects of Erroneous Administration of Potent Inhibitors of Bone Resorption in People With Osteomalacia
| Reference | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|
| Age/gender | 52 F | 42 F | 71 F | 54 F | 48 M |
| Cause of osteomalacia | Vitamin D deficiency | Vitamin D deficiency | Oncogenic osteomalacia | Oncogenic osteomalacia | Fanconi syndrome |
| Antiresorptive treatment | Pamidronate 60 mg ×1 | Alendronate 1 year ‐ oral | Zoledronate 4 mg ×2 | Bisphosphonate (not specified) 2 months ‐ oral | Denosumab 60 mg ×1 |
| Biochemical changes a | ↓Ca | ↓Ca, ↑PTH, ALP | ↓Ca, Pi ↑PTH, ALP | No change | ↓Ca, Pi |
| Skeletal symptoms a | Not reported | ↑ Disability & weakness | Not reported | No change | Not reported |
| Spinal BMD T‐score | −1.7 | −2.4 | Not reported | −4.5 | −3.2 |
| Other | Postgastric bypass | Postgastric bypass | Also had metastatic breast cancer | Myeloma |
a
Indicates changes in symptoms and plasma biochemistry after administration of the antiresorptive agent.
ALP = alkaline phosphatase; Ca = calcium; F = female; M = male; Pi = phosphate; PTH = parathyroid hormone.